Thermo Fisher Scientific Inc. (TMO)
| Market Cap | 222.35B +27.8% |
| Revenue (ttm) | 46.34B +7.2% |
| Net Income | 6.97B +5.8% |
| EPS | 18.58 +7.4% |
| Shares Out | 369.75M |
| PE Ratio | 32.56 |
| Forward PE | 23.04 |
| Dividend | $1.88 (0.31%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 477,174 |
| Open | 599.21 |
| Previous Close | 605.00 |
| Day's Range | 595.00 - 602.70 |
| 52-Week Range | 435.27 - 643.99 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 631.42 (+5.0%) |
| Earnings Date | Jul 23, 2026 |
About TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analy... [Read more]
Financial Performance
In 2025, Thermo Fisher's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for TMO stock is "Buy." The 12-month stock price target is $631.42, which is an increase of 5.00% from the latest price.
News
Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist
LUXEMBOURG & NEW YORK & PARIS--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business fro...
Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, ...
Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost
Thermo Fisher Scientific is eyeing a 15%-20% increase in its customer base in India over the next five years, betting on the growing biopharma research and manufacturing ecosystem, the head of its I...
Thermo Fisher price target raised to $650 from $600 at Stifel
Stifel raised the firm’s price target on Thermo Fisher (TMO) to $650 from $600 and keeps a Buy rating on the shares.
Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities ...
Thermo Fisher price target raised to $600 from $510 at Piper Sandler
Piper Sandler raised the firm’s price target on Thermo Fisher (TMO) to $600 from $510 and keeps a Neutral rating on the shares. The firm is raising its price target…
Thermo Fisher price target raised to $650 from $620 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Thermo Fisher (TMO) to $650 from $620 and keeps an Overweight rating on the shares following Q2 results. The firm cited improved…
Thermo Fisher price target raised to $580 from $490 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Thermo Fisher (TMO) to $580 from $490 and keeps a Sector Perform rating on the shares after its Q2…
Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the global launch of Thermo Scientific™ InstaFlux™, an integrated media-on-demand enrichment workflow that helps food microbio...
Thermo Fisher price target raised to $650 from $625 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Thermo Fisher (TMO) to $650 from $625 and keeps an Overweight rating on the shares following the Q2 report. The…
Thermo Fisher price target raised to $650 from $630 at BofA
BofA raised the firm’s price target on Thermo Fisher (TMO) to $650 from $630 and keeps a Buy rating on the shares after “a strong quarter with very broad-based results.”…
Thermo Fisher raises FY26 EPS to $24.93-$25.33, consensus $24.85
From a previous range of $24.64-$25.12. Raises FY26 revenue to $47.4-$48.1B from a prior range of $47.30B-$48.10B.
Thermo Fisher price target raised to $630 from $585 at Jefferies
Jefferies analyst Tycho Peterson raised the firm’s price target on Thermo Fisher (TMO) to $630 from $585 and keeps a Buy rating on the shares. The firm says there was…
Thermo Fisher Scientific Earnings Call Transcript: Q2 2026
Q2 delivered double-digit revenue and EPS growth, with strong performance across all segments and geographies. Full-year guidance was raised for both revenue and EPS, reflecting robust customer activity, successful acquisitions, and continued innovation.
Thermo Fisher Scientific Earnings release: Q2 2026
Thermo Fisher Scientific released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Thermo Fisher Scientific Quarterly report: Q2 2026
Thermo Fisher Scientific has published its Q2 2026 quarterly earnings report on July 23, 2026.
Thermo Fisher beats quarterly estimates as customer demand improves
Thermo Fisher Scientific beat Wall Street estimates for second-quarter profit and revenue on Thursday, as improving customer demand lifted sales across all its business segments.
Thermo Fisher reports Q2 adjusted EPS $6.03, consensus $5.71
Reports Q2 revenue $11.99B, consensus $11.7B. “We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellent execution and the...
Thermo Fisher Scientific Reports Second Quarter 2026 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2026. Second...
Thermo Fisher Scientific Announces Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0....
Thermo Fisher named short-term buy idea at Deutsche Bank
Deutsche Bank placed a “Catalyst call: Buy” on shares of Thermo Fisher (TMO) as a short-term investment idea. The set-up for the stock entering Q2 earnings is improved with sentiment…
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
SAN FRANCISCO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Applied Biosystems™ RapidINTEL™ Plus Cartridge has received approval from the Fe...
Thermo Fisher price target lowered to $570 from $575 at Evercore ISI
Evercore ISI lowered the firm’s price target on Thermo Fisher (TMO) to $570 from $575 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life…
Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
Roth Capital analyst Adam Walsh keeps a Buy rating and $20 price target on shares of Arcturus Therapeutics (ARCT). The Thermo Fisher (TMO) collaboration on ARCT-032 Phase 3 is viewed…
Arcturus announces collaboration with Thermo Fisher to advance ARCT-032
Arcturus Therapeutics (ARCT) announced a strategic collaboration with Thermo Fisher Scientific (TMO) to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ inve...